Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade.

King CR, McNeal JE, Gill H, Brooks JD, Srinivas S, Presti JC Jr.

Urology. 2006 Jun;67(6):1229-34.

PMID:
16765184
2.

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.

Patel DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR.

J Clin Oncol. 2005 Sep 1;23(25):6157-62.

PMID:
16135482
3.

Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer.

Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, Caldwell M, Peehl DM.

Cancer Lett. 2005 Sep 28;227(2):213-22.

PMID:
16112424
4.

Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution?

Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL.

J Urol. 2005 Jun;173(6):1969-74.

PMID:
15879794
5.

Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy.

Lee KL, Marotte JB, Ferrari MK, McNeal JE, Brooks JD, Presti JC Jr.

Urology. 2005 Feb;65(2):311-5.

PMID:
15708044
6.

Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables.

Ferrari MK, McNeal JE, Malhotra SM, Brooks JD.

Urology. 2004 Oct;64(4):749-53.

PMID:
15491714
7.

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J.

J Urol. 2004 Oct;172(4 Pt 1):1297-301.

PMID:
15371827
8.

Time trends in pathologic features of radical prostatectomy--impact of family history.

Marotte JB, Ferrari MK, McNeal JE, Brooks JD, Presti JC Jr.

Urol Oncol. 2004 May-Jun;22(3):169-73.

PMID:
15271309
9.

Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.

Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM.

Am J Pathol. 2004 Jun;164(6):2003-12.

10.

Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.

King CR, McNeal JE, Gill H, Presti JC Jr.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):386-91.

PMID:
15145152
11.

Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies.

Hong YM, Lai FC, Chon CH, McNeal JE, Presti JC Jr.

Urol Oncol. 2004 Jan-Feb;22(1):7-10.

PMID:
14969796
12.

Elevated expression of inhibin alpha in prostate cancer.

Risbridger GP, Shibata A, Ferguson KL, Stamey TA, McNeal JE, Peehl DM.

J Urol. 2004 Jan;171(1):192-6.

PMID:
14665874
13.
14.

Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases.

Iczkowski KA, Ferguson KL, Grier DD, Hossain D, Banerjee SS, McNeal JE, Bostwick DG.

Am J Surg Pathol. 2003 Dec;27(12):1523-9.

PMID:
14657711
15.

Genetic profiling of Gleason grade 4/5 prostate cancer: which is the best prostatic control tissue?

Stamey TA, Caldwell MC, Fan Z, Zhang Z, McNeal JE, Nolley R, Chen Z, Mahadevappa M, Warrington JA.

J Urol. 2003 Dec;170(6 Pt 1):2263-8.

PMID:
14634393
16.

[Origin and development of carcinoma of the prostate].

McNeal JE.

Aktuelle Urol. 2003 Mar;34(2):81-2. German. No abstract available.

PMID:
14579838
17.
18.

Intraoperative lymph node staging of prostate cancer: the case against.

Garrett KL, McNeal JE, Cohen RJ.

ANZ J Surg. 2003 May;73(5):263-6.

PMID:
12752279
20.

Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.

Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA, Stamey TA.

J Urol. 2003 Apr;169(4):1316-9.

PMID:
12629351
21.
22.

Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression.

Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM.

Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):23-7.

23.

Epithelial differentiation of the lower urinary tract with recognition of the minor prostatic glands.

Cohen RJ, Garrett K, Golding JL, Thomas RB, McNeal JE.

Hum Pathol. 2002 Sep;33(9):905-9.

PMID:
12378515
24.

Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis.

Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl DM.

Prostate. 2002 Sep 1;52(4):269-78.

PMID:
12210487
25.

Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens.

Wise AM, Stamey TA, McNeal JE, Clayton JL.

Urology. 2002 Aug;60(2):264-9.

PMID:
12137824
26.

Use of extended systematic sampling in patients with a prior negative prostate needle biopsy.

Chon CH, Lai FC, McNeal JE, Presti JC Jr.

J Urol. 2002 Jun;167(6):2457-60.

PMID:
11992057
27.

Application of tissue-marking ink to prostate biopsy specimens.

Terris MK, McNeal JE.

Prostate. 2002 Mar 1;50(4):247-51.

PMID:
11870803
28.

Polyamines in prostatic epithelial cells and adenocarcinoma; the effects of androgen blockade.

Cohen RJ, Fujiwara K, Holland JW, McNeal JE.

Prostate. 2001 Dec 1;49(4):278-84.

PMID:
11746274
30.

Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.

Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z.

J Urol. 2001 Dec;166(6):2171-7.

PMID:
11696729
31.

Patterns of spread of adenocarcinoma in the prostate as related to cancer volume.

McNeal JE, Haillot O.

Prostate. 2001 Sep 15;49(1):48-57.

PMID:
11550210
32.

Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement.

Shibata A, Stamey TA, McNeal JE, Cheng I, Peehl DM.

J Urol. 2001 Oct;166(4):1560-4.

PMID:
11547131
33.
35.

The role of intraductal carcinoma in the natural history of prostatic adenocarcinoma.

McNeal JE.

Eur Urol. 2001 Apr;39 Suppl 4:4. No abstract available.

PMID:
11340276
36.

Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma.

McNeal JE, Cohen RJ, Brooks JD.

Hum Pathol. 2001 Apr;32(4):441-6.

PMID:
11331962
38.

Immunostains after glutaraldehyde-based tissue fixation.

Cohen RJ, Fischer G, McNeal JE.

Hum Pathol. 2001 Feb;32(2):242-3. No abstract available.

PMID:
11230717
39.

Prostate secretory granules in normal and neoplastic prostate glands: a diagnostic aid to needle biopsy.

Cohen RJ, Beales MP, McNeal JE.

Hum Pathol. 2000 Dec;31(12):1515-9.

PMID:
11150377
40.

Sarcomatoid renal cell carcinoma of papillary origin. A case report and cytogenic evaluation.

Cohen RJ, McNeal JE, Susman M, Sellner LN, Iacopetta BJ, Weinstein SL, Dawkins HJ.

Arch Pathol Lab Med. 2000 Dec;124(12):1830-2.

PMID:
11100068
41.
42.

Assessment of morphometric measurements of prostate carcinoma volume.

Noguchi M, Stamey TA, McNeal JE, Yemoto CE.

Cancer. 2000 Sep 1;89(5):1056-64.

PMID:
10964336
43.

Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.

Dawkins HJ, Sellner LN, Turbett GR, Thompson CA, Redmond SL, McNeal JE, Cohen RJ.

Prostate. 2000 Sep 1;44(4):265-70.

PMID:
10951489
44.

Identification of the glycosaminoglycan keratan sulfate in the prostatic secretory cell.

Cohen RJ, Holland JW, Redmond SL, McNeal JE, Dawkins HJ.

Prostate. 2000 Aug 1;44(3):204-9.

PMID:
10906736
45.

Modified extrafascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers <2 cm(3).

Villers A, Stamey TA, Yemoto C, Rischmann P, McNeal JE.

Eur Urol. 2000 Jul;38(1):64-73.

PMID:
10859444
46.

Variant chromophobe renal cell carcinoma.

Cohen RJ, Weinstein S, Robertson T, Sellner LN, Dawkins HJ, McNeal JE.

Arch Pathol Lab Med. 2000 Jun;124(6):904-6.

PMID:
10835533
47.

Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.

Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM.

J Urol. 2000 Apr;163(4):1155-60.

PMID:
10737486
48.
49.

Luminal contents of benign and malignant prostatic glands: correspondence to altered secretory mechanisms.

Cohen RJ, McNeal JE, Redmond SL, Meehan K, Thomas R, Wilce M, Dawkins HJ.

Hum Pathol. 2000 Jan;31(1):94-100.

PMID:
10665919
50.

Biological determinants of cancer progression in men with prostate cancer.

Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM.

JAMA. 1999 Apr 21;281(15):1395-400.

PMID:
10217055

Supplemental Content

Loading ...
Support Center